Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
2(100.0%)
2Total
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06078514Recruiting

Sexual Function and Quality of Life After LEEP: a Prospective Multi-Center Study

Role: collaborator

NCT04978259Phase 4Unknown

SOLIDARITY Finland Long-COVID (Remdesivir Long-term Follow-up Study of COVID Patients)

Role: collaborator

NCT05220280Phase 4Unknown

SOLIDARITY Finland Plus Long-COVID

Role: collaborator

NCT01536769Completed

Intestinal and Nasal Microbiota of Patients With Idiopathic Parkinson's Disease

Role: collaborator

All 4 trials loaded